Orabloc (Articaine Hydrochloride, Epinephrine)

Articaine blocks voltage‑gated sodium channels on neuronal membranes, preventing the initiation and propagation of action potentials. This reversible blockade stops nerve impulse transmission, producing loss of sensation in the targeted area. The epinephrine component causes local vasoconstriction, prolonging the anesthetic effect and reducing systemic absorption.

The dosage of Orabloc is determined by the prescribing dentist based on the specific procedure, patient age, weight, and health status. Standard practice follows established maximum limits for articaine with epinephrine, and the prescriber adjusts the volume injected to achieve adequate anesthesia while staying within safety guidelines.

Safety data for articaine in pregnancy and lactation are limited, and the product is classified as a Category C or unknown. Clinicians should weigh potential benefits against risks, and use the lowest effective dose only when the anticipated benefit justifies exposure. Breastfeeding mothers should consult their healthcare provider before use.

To place an order, submit an enquiry on the Orabloc product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both articaine (Orabloc) and lidocaine are amide‑type local anesthetics used in dentistry. Articaine has a higher lipid solubility and a thiophene ring, allowing deeper tissue penetration and a slightly faster onset. Lidocaine is longer established, while articaine often requires lower volumes for comparable effect, though both have similar safety profiles when used correctly.

Orabloc should be stored at room temperature, below 25 °C, in its original sealed container. Protect the product from direct sunlight, moisture, and extreme temperature fluctuations. Do not freeze the solution, and keep it out of reach of children to maintain potency and safety.

Orabloc is administered by a qualified dental professional via intraoral injection into the target tissue. The solution is typically deposited in the periodontal ligament, mucobuccal fold, or directly around the tooth apex, depending on the required block. Proper aseptic technique and dosage calculation are essential for effective anesthesia.

The most serious risks include allergic reactions ranging from rash to anaphylaxis, cardiovascular events such as hypertension, arrhythmias, or tachycardia due to epinephrine, and rare neurological complications like persistent paresthesia or methemoglobinemia. Immediate medical attention is required if any of these symptoms occur.

Patients with a known hypersensitivity to amide‑type local anesthetics or epinephrine should avoid Orabloc. It is also contraindicated in individuals with uncontrolled severe hypertension, certain cardiac arrhythmias, or those taking non‑selective MAO inhibitors. Pregnant or breastfeeding women should use only after careful risk‑benefit assessment by their clinician.